Keryx Biopharmaceuticals stockholders approve merger with Akebia Therapeutics
Keryx Biopharmaceuticals announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter aliaAkebia Therapeutics. Upon completion of the merger, Keryx stockholders will receive 0.37433 common shares of Akebia for each share of Keryx they own. December 11, 2018